Our look is new. Our purpose is the same. Learn more about our brand evolution.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Saint Louis University’s (SLU) Center for World Health and Medicine, announced that they […]
By June Kinoshita (from FSH Watch Fall 2015 issue) Click on image below to view full size. In 2013-2014, the FSH Society funded a study led by Doris Leung, MD, […]
According to a Boston Business Journal story, Cambridge, Massachusetts-based biotech Acceleron Pharma has plans to test its ACE-083 compound in facioscapulohumeral muscular dystrophy patients in a phase 2 clinical trial later […]
Insights on symptoms, biology, and quality of life By Yi-Wen Chen, PhD and Jean Mah, MD While most people with FSHD develop muscle weakness during late teen years or adulthood, […]
Peter Jones, PhD, and Charis Himeda, PhD, found themselves unexpectedly in the media spotlight last week after publication of their paper on the application of CRISPR technology in FSHD cells. In […]
